Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 63,530 shares, a decline of 46.6% from the May 31st total of 119,012 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily volume of 126,040 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

A number of analysts have commented on APRE shares. Oppenheimer began coverage on Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 target price on the stock. HC Wainwright cut their price target on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Wedbush cut their price target on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Monday, April 20th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.07.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE opened at $0.82 on Tuesday. The firm has a market cap of $10.14 million, a P/E ratio of -0.53 and a beta of 1.51. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.22. The firm’s 50 day moving average price is $0.84 and its 200 day moving average price is $0.82.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. As a group, equities analysts predict that Aprea Therapeutics will post -0.84 EPS for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

Several institutional investors have recently added to or reduced their stakes in APRE. AIGH Capital Management LLC lifted its position in Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after buying an additional 645,000 shares during the period. DRW Securities LLC purchased a new stake in Aprea Therapeutics in the 4th quarter valued at about $103,000. Finally, Jane Street Group LLC purchased a new stake in Aprea Therapeutics in the 4th quarter valued at about $40,000. 34.19% of the stock is currently owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.